Morgan Stanley’s Liminatus Pharma LIMN Stock Holding History

Morgan Stanley’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.22K	Buy	+1,936	New	+$9.8K	﹤0.01%	7173

Other funds holding LIMN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Cheviot Value Management Beverly Hills, California $1.03B AUM 18.09% 1-Year Est. Return

Morgan Stanley's LIMN Position: Q3 2026 in Review

Morgan Stanley opened a new position in Liminatus Pharma (LIMN) in Q3 2026: 1,936 shares worth $7.22K. The stake represents ﹤0.01% of the portfolio and ranks #7173 among its holdings.

9 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.

Morgan Stanley held 1,936 shares of Liminatus Pharma worth $7.22K as of Q3 2026.
Liminatus Pharma was a new Morgan Stanley position in Q3 2026.
Liminatus Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #7173 holding.
9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.